- Farber’s Disease is a rare lysosomal storage disorder, and the treatment landscape includes supportive medications, enzyme replacement therapies, and, in severe cases, surgical interventions such as bone marrow transplants
- Market growth is fueled by advancements in genetic research, rising awareness of rare diseases, and improved access to orphan drug designations and funding
- North America is expected to dominate the Farber’s Disease drug market due to well-established healthcare systems, availability of advanced therapies, and strong presence of key pharmaceutical players
- Europe follows closely, supported by increased rare disease initiatives and favorable regulatory frameworks
- The medication segment is projected to dominate the market with a share of 63.4% in 2024, due to the increasing reliance on pharmacological management for symptom relief and inflammation control
